E
Enzymatica AB (publ)
STO:ENZY
Enzymatica AB (publ)
STO:ENZY
Price:
1.85
SEK
-3.9%
Market Cap:
kr449.1m
Relative Value
The Relative Value of one ENZY stock under the Base Case scenario is 1.54 SEK. Compared to the current market price of 1.85 SEK, Enzymatica AB (publ) is Overvalued by 17%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ENZY
Relative Value
Base Case
1.54
SEK
Overvaluation 17%
E
Multiples Across Competitors
ENZY Competitors Multiples
Enzymatica AB (publ) Competitors
Enzymatica AB (publ) Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
E
|
Enzymatica AB (publ)
STO:ENZY
|
449.1m SEK | 8.5 | -8.3 | -7.6 | -7.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD | 15.3 | 48.3 | 32.5 | 34.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.8B CHF | 4.6 | 30.1 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD | 4.7 | 16.6 | 10.4 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.3B CHF | 5.3 | 21.3 | 13.1 | 16.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 5.2 | 32.1 | 15.3 | 22.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.7 | 10 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 6.9 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
